The first cancer genome paper was published in 2008, and in just 13 years the power of sequencing and analytics has established genomics as an essential tool in our understanding and treatment of cancers.
From developing a deeper understanding of oncogenic drivers, helped to develop diagnostic capabilities, and find unique precision oncology drugs which should increase efficacy and prognostic outcomes.
Join us for Cancer Genomics ONLINE as we share the latest work from global researchers who are mapping the cancer genome and leading the fight against this deadly disease.
From this series, you will have heard recent case studies that develop our understanding of cancer genome evolution, how functional genomics and gene editing is giving insights for the next era of therapeutics, and how genomics and inform clinical practice.
Webinar 1: Discovering the cancer genome
15th April – 3pm BST/ 4pm CEST/ 10am EDT
While sequencing technologies have enabled the study of genomic alterations in cancer, a lot remains unknown about the role those mutations play and how they affect cancer evolution, particularly within non-coding regions.
This webinar will focus on global research that interrogates the cancer genome using big data and analytic tools to find genes of interest and how we can uncover the role it plays in the complex molecular networks of cancer.
Cancer Evolution and Immune Escape – Nicholas McGranahan, Lab Head, Cancer Genome Evolution Research Group, UCL
Finding the origins of cancer – Sam Behjati, Group Leader, Wellcome Sanger
Germline influence on tumor evolution – Hannah Carter, Associate Professor, UC San Diego
Webinar 2: Genomics-guided target ID and cancer drug development
22nd April – 3pm BST/ 4pm CEST/ 10am EDT
The promise of precision medicine for cancer patients relies on precision oncology drugs to be developed, tested, and patient populations identified.
This webinar will focus on genomic cancer biomarker discovery, validation, and development of the next era of precision oncology drugs.
SEMMs and DIVoS, novel tools in preclinical drug discovery – Danilo Maddalo, Head of Laboratory, Translational Oncology, Roche/ Genentech
Functional Genomics Centre delivers novel targets and uncovers resistance to cancer treatments using pooled CRISPR screening – Miika Ahdesmäki, Associate Director, Functional Genomics Centre, AstraZeneca
Accelerate functional genomics studies with simultaneous capture of CRISPR guides and gene expression profiles at single cell resolution – Stephen Hague, Senior Science and Technology Advisor, 10x Genomics
Webinar 3: Clinical cancer genomics
29th April – 3pm BST/ 4pm CEST/ 10am EDT
This webinar will focus on how the cancer genome impacts clinical decision making, cancer prevention, diagnostic development and how these aspects are integrating into clinics now, and in the future.
Harnessing germline genomics for precision prevention of cancer – Clare Turnbull, Professor of Translational Cancer Genetics, Institute of Cancer Research
How the cancer genome can reveal germline susceptibility to cancer, using lung cancer and glioma as examples – Patrick Benusiglio, Head of Clinical Cancer Genetics, Assistance Publique Hôpitaux de Paris
High-content genomic testing for stratification of treatment in cancer patients – Mike Hubank, Head of Clinical Genomics (Research), The Royal Marsden NHS Foundation Trust
Speakers
Nicholas McGranahan, Lab Head, Cancer Genome Evolution Research Group, UCL
Sam Behjati , Group Leader, Wellcome Sanger Institute
Hannah Carter, Associate Professor, UC San Diego
Danilo Maddalo, Head of Laboratory, Translational Oncology, Roche/ Genentech
Miika Ahdesmäki, Associate Director, Functional Genomics Centre, AstraZeneca
Stephen Hague, Senior Science and Technology Advisor, 10X Europe
Clare Turnbull, Professor of Translational Cancer Genetics, Institute of Cancer Research
Patrick Benusiglio, Head of Clinical Cancer Genetics, Assistance Publique Hôpitaux de Paris
Mike Hubank, Head of Clinical Genomics (Research), The Royal Marsden NHS Foundation Trust
